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a b s t r a c t
Background: The use of drug-coated balloons (DCBs) in small-vessel coronary artery disease (SVD) remains controversial.
Methods: We performed a meta-analysis of all randomized controlled trials (RCTs) reporting the outcomes of DCB
vs. DES in de-novo SVD. We included a total of 5 RCTs (1459 patients), with (DCB n = 734 and DES n = 725).
Results: Over a median follow-up duration of 6 months, DCB was associated with smaller late lumen loss (LLL)
compared with DES (mean difference −0.12 mm) (95% conﬁdence intervals (CI) [−0.21, −0.03 mm], p =
0.01). Over a median follow-up of 12 months, both modalities had similar risk of major adverse cardiovascular
events (MACE) (8.7% vs. 10.2%; odds ratio (OR): 0.94, 95% CI [0.49–1.79], p = 084), all-cause mortality (1.17%
vs. 2.38%; OR: 0.53, 95% CI [0.16–1.75], p = 0.30), target lesion revascularization (TLR) (7.9% vs. 3.9%; OR: 1.26,
95% CI [0.51–3.14], p = 0.62), and target vessel revascularization (TVR) (8.2% vs. 7.8%; OR: 1.06, 95% CI
[0.40–2.82], p = 0.91). DCBs were associated with lower risk of myocardial infarction (MI) compared with DES
(1.55% vs. 3.31%; OR: 0.48, 95% CI [0.23–1.00], p = 0.05, I2 = 0%).
Conclusion: PCI of SVD with DCBs is associated with smaller LLL, lower risk of MI, and similar risk of MACE, death,
TLR, and TVR compared with DES over one year. DCB appears as an attractive alternative to DES in patients with
de-novo SVD, but long-term clinical data are still needed.
© 2021 Elsevier Inc. All rights reserved.

1. Introduction
Small vessel coronary artery disease (SVD) is often treated with percutaneous coronary intervention (PCI) [1], but is a complex lesion subset and is associated with high risk of major adverse cardiovascular
events (MACE). Current treatment options for SVD include standard
balloon angioplasty, drug-eluting stents (DES), and drug-coated balloons (DCBs). Balloon angioplasty is associated with high restenosis
rates due to elastic recoil and adverse remodeling [2]. DES have been associated with worse outcomes in smaller compared with larger vessels
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[3–5] likely due to the small vessel caliber with little room to accommodate neointimal tissue growth.
Drug-coated balloon (DCB)-only PCI has emerged as an alternative
treatment option to de-novo coronary artery disease and in-stent restenosis (ISR). [6–8] However, the outcomes with DCB in SVD have been
controversial [9–15]. We performed a systematic review and metaanalysis to compare the angiographic and clinical outcomes of DCB vs.
DES in SVD.
2. Methods
The current meta-analysis was performed according to the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses guidelines
(PRISMA) [16]. We performed a systematic computerized search limited to the English language through Medline, Embase, and Cochrane
databases from January 2000 to January 2021 using the following search
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terms separately and in combination; “Drug-eluting balloon,” “DEB,”
“drug-coated balloon,” “DCB,” “paclitaxel-coated balloon,” “PCB,”
“small-vessel coronary artery disease,” and “small-vessel disease.” We
screened the retrieved studies' bibliographies, previous reviews, and
ClinicalTrials.gov for any relevant studies not found through the initial
search.
2.1. Study selection and data collection
We included randomized controlled trials (RCTs) that compared
outcomes with DCB vs. DES in the treatment of de-novo SVD (reference
vessel diameter ≤ 3 mm) (Fig. S1). In the DCB arm, stenting was allowed
only as a bailout strategy in case of suboptimal results, deﬁned as persistent residual stenosis, vessel recoil, or ﬂow-limiting dissection.
The data were extracted by two independent investigators (KB, MM)
and conﬁrmed by a third investigator (MS). The data included baseline
study characteristics, baseline clinical and angiographic characteristics
of the included patients and lesions, and the outcomes of interest. Discrepancies among investigators were settled by consensus. The included studies' bias risk was assessed using the Cochrane risk
assessment tool for RCTs (Table S2) [17]. Potential publication bias
was assessed using the Egger test by visually examining the funnel
plots (Fig. S2).
2.2. Study outcomes
The clinical outcomes of the current study included periprocedural
myocardial infarction (MI) and long-term outcomes, including MACE,
target lesion revascularisation (TLR), target vessel revascularisation
(TVR), MI, all-cause mortality, and angiographic late lumen loss (LLL)
measured by quantitative coronary angiography. Deﬁnitions of outcomes by each study included are shown in Table S1. Results were reported at the longest follow-up time available and according to the
intention-to-treat analysis.
2.3. Statistical analysis
Statistical analysis was conducted using Review Manager software
(Version 5.3.5. Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2014). Descriptive analyses were conducted using frequencies for categorical variables and means with standard deviations
(SD) for continuous variables. Categorical variables were compared
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using Fisher's exact or chi-square tests, while continuous variables
were analysed using the two-sample t-test. Tests were two-tailed, and
a p-value of ≤0.05 was considered statistically signiﬁcant.
Odds ratios (ORs) or mean differences (MD) with 95% conﬁdence intervals (CIs) were presented as summary statistics. Statistical heterogeneity across trials was assessed by I2 statistics, with I2 statistic values
<25%, 25% to 50%, and >50% considered as low, moderate, and a high
degree of heterogeneity, respectively. The DerSimonian and Laird
random-effects model and inverse variance model were used to calculate OR and MD, respectively. We performed a sensitivity analysis excluding the study by Cortese et al. given use of a ﬁrst-generation DCB
and lack of adequate lesion preparation (25%) [11]. We performed another sensitivity analysis comparing DCBs vs. second-generation DES
[10,12,14].
3. Results
We included a total of 5 RCTs (1459 patients), with (DCB n = 734
and DES n = 725). The characteristics of the included studies are described in Table 1. Only three studies compared the outcomes with
DCB vs. second-generation DES [10,12,14]. We used both the 6 months
(for angiographic outcomes) and 3 years (for clinical outcomes) publications for the BELLO study [13,18]. Bailout stenting in the DCB-only
group occurred in 10% of patients ranging between 5.1% to 35.7%, with
recent studies reporting fewer bailout stenting events. The baseline clinical and angiographic characteristics of the included patients and lesions
are summarized in Table 2.
3.1. Outcomes
Both technical (98.8 vs. 99.2%, p = 0.96) and procedural (97.1% vs.
98.1%, p = 0.26) success was similar between both groups. There was
no difference in the risk of periprocedural MI with DCB compared
with DES (2.2% vs. 3.9%; OR: 0.56, 95% CI [0.21, 1.48], p = 0.25, I2 =
0%) (Figs. 1 and 2).
During a median follow-up duration of 6 months (range 6–9
months), DCBs were associated with smaller LLL compared with DES
(MD: −0.12 mm (95% CI [−0.21, −0.03 mm], p = 0.01, I2 = 56%)).
Over a median follow-up of 12 months (range 9–36 months), both
arms had similar risk of MACE (8.7% vs. 10.2%; OR: 0.94, 95% CI [0.49,
1.79], p = 0.84, I2 = 59%), all-cause mortality (1.17% vs. 2.38%; OR:
0.53, 95% CI [0.16, 1.75], p = 0.30, I2 = 0%), TLR (7.9% vs. 3.9%; OR:

Table 1
Characteristics of the included studies.
Study

Trial/registry

Study
type

Number of
patients with
DCB/DES

Balloon/stent type

Country
(# of
centers)

Follow-up
time
(months)

Enrolment
dates

Vessel
size

Bailout
stenting %

Primary
endpoint

Cortese et al.
2020

PICCOLETO II

RCT

118/114

Europe
(5)

12

May 2015 –
May 2018

2.00–2.75
mm

6.8%

In-lesion LLL
at 6 months

Tian et al. 2020

RESTORE-SVD

RCT

116/114

Elutax DCB (AR Baltic Medical,
Vilnius, Lithuania)/Xience DES
(Boston Scientiﬁc, USA)
RESTORE DCB (Cardionovum,
Germany)/RESOLUTE DES
(Medtronic, USA)

China
(12)

24

August
2016 – June
2017

2.25–2.75
mm

5.2%

Jeger et al. 2018

BASKET-SMALL 2

RCT

382/376

Europe
(14)

12

April 2012 –
February
2017

<3 mm in 5.1%
diameter

Latib et al. 2012

BELLO

RCT

90/92

Italy
(15)

6–36
months

Not
discussed

<2.8 mm

20.2%

Cortese et al.
2010

PICCOLETO

RCT

28/29

SeQuent Please DCB (B. Braun,
Germany)/Xience (Abbott
Vascular, USA) or Taxus or
Promus DES (Boston Scientiﬁc,
USA)
IN.PACT Falcon DCB
(Medtronic, USA)/Taxus Liberte
DES (Boston Scientiﬁc, USA)
Dior DCB (Eurocor,
Germany)/Taxus DES (Boston
Scientiﬁc, USA)

Percentage
diameter
stenosis at 9
months
MACE at 12
months

Italy (1)

9

August 2007
and August
2008

≤2.75 mm

35.7%

DCB: drug-coated balloon; DES: drug-eluting stent; LLL: late lumen loss; MACE: major adverse cardiovascular events; RCT: arandomized controlled trial.
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Table 2
Baseline characteristics of the included patients and lesions.

Age mean ± SD
Men %
Multivessel Disease %
Hypertension %
Dyslipidemia %
Diabetes %
Current smoking %
Previous MI %
Family history of CAD %
Prior CABG
Prior PCI
Vessel involved
LAD
LCx
RCA
Diagonal
OM/Ramus Intermedius
PDA/PL
LVEF Baseline mean ± SD
Lesion/procedural characteristics
Bifurcation lesion
AHA B2/C Lesion
Minimal luminal diameter (mm)
Reference vessel diameter (mm)
Lesion length (mm)
Predilation
Bailout stenting
Procedural success
Lesion success

DCB (n = 734)

DES (n = 725)

p-value

65.30 ± 10.23
74.68
70.96 [588]
78.01
66.02
35.79
22.11
38.46
36.78
7.37
53.93

66.47 ± 10.40
73.37
66.46 [582]
81.75
64.76
37.02
20.16
32.12
30.73
7.56
52.69

0.030
0.609
0.110
0.086
0.652
0.664
0.396
0.013
0.017
0.969
0.673

28.83
40.47
17.44
14.24 [206]
13.54 [206]
21.31 [206]
58.18 ± 4.77

27.12
39.28
19.20
10.97 [206]
17.22 [206]
22.26 [206]
59.60 ± 4.219

0.503
0.681
0.423
0.395
0.369
0.909
p < 0.001

8.31 [528]
44.47 [234]
0.61 ± 0.25
2.42 ± 0.25
12.91 ± 6.46
80.21 [738]
10.04 [328]
97.11 [738]
98.85 [262]

9.84 [519]
46.67 [235]
0.61 ± 0.26
2.41 ± 0.29
12.81 ± 6.27
78.93 [731]
0.9 [228]
98.13 [731]
99.20 [257]

0.451
0.700
1.000
0.480
0.764
0.587
p < 0.001
0.267
0.967

CABG: Coronary artery bypass graft; CAD: coronary artery disease; DCB: drug-coated balloon; DES: drug-eluting stent; LAD: left anterior descending; LCx: left circumﬂex; LVEF:
Left ventricular ejection fraction; MI: Myocardial infarction; OM: obtuse marginal; PCI:
Percutaneous coronary intervention; PDA: posterior descending artery; PL: posterolateral;
RCA: right coronary artery.
Numbers between square brackets represent the number of subjects with a reported variable when different from the baseline.

1.26, 95% CI [0.51, 3.14], p = 0.62, I2 = 54%), and TVR (8.2% vs. 7.8%; OR:
1.06, 95% CI [0.40, 2.82], p = 0.91, I2 = 46%) (Figs. 2 and 3). DCB was associated with lower risk of MI compared with DES (1.55% vs. 3.31%; OR:
0.48, 95% CI [0.23, 1.00], p = 0.05, I2 = 0%).
On sensitivity analysis and exclusion of the study by Cortese et al.
2010, both modalities had similar risk of MACE (OR: 0.74, 95% CI [0.43,

1.27], p = 0.28, I2 = 39%), all-cause mortality (OR: 0.46, 95% CI [0.13,
1.71], p = 0.25, I2 = 0%), TLR (OR: 0.87, 95% CI [0.40, 1.89], p = 0.72,
I2 = 23%), and TVR (OR: 0.68, 95% CI [0.29, 1.59], p = 0.38, I2 = 0%).
DCBs remained associated with lower risk of MI compared with DES
(OR: 0.43, 95% CI [0.20, 0.92], p = 0.03, I2 = 0%). This sensitivity analysis
yielded similar results with much reduction in heterogeneity (Fig. S3).
DCB had similar risk of MACE (OR: 0.97, 95% CI [0.61, 1.53], p = 0.89,
I2 = 0%), all-cause mortality (OR: 0.60, 95% CI [0.07, 4.90], p = 0.63, I2 =
0%), TLR (OR: 1.29, 95% CI [0.53, 3.18], p = 0.57, I2 = 0%), TVR (OR: 0.76,
95% CI [0.42,1.39], p = 0.37, I2 = 0%), and MI (OR: 0.48, 95% CI [0.21,
1.08], p = 0.08, I2 = 0%) compared with second-generation DES
(Fig. S4). A summary of the study results is shown in Fig. 4.

4. Discussion
The main ﬁndings of our study can be summarized as follows: 1) the
use of DCB in SVD PCI is associated with smaller late lumen loss over 6
months and a lower incidence of MI during a median follow-up of 12
months, 2) both DCBs and DES are associated with a similar risk of
MACE, death, TLR, and TVR when used in PCI of SVD, 3) When comparing DCBs and second-generation DES, both modalities were comparable
with a similar risk of clinical events at a median follow-up of 12 months.
In our analysis, DCBs were associated with lower risk of MI compared with DES during a median follow-up of 1 year. DES are currently
commonly used in SVD PCI. Other options include regular balloon angioplasty or medical therapy, which might not be adequate in severely
symptomatic patients or when the goal is to achieve complete revascularization. However, DES may have limitations in SVD, as suggested by
the higher MI risk with DES in our study. DES are associated with neointimal hyperplasia and late occurrence of neoatherosclerosis and stent
thrombosis, which can be exaggerated in small vessels with little
room to accommodate the neointima [19]. DES had more LLL in our
study. The risk of ISR is higher in smaller caliber vessels, longer lesions,
and patients with diabetes mellitus, that are commonly associated with
SVD [20]. Previous studies have demonstrated that the risk of MACE, including MI, was almost double in small vessels as compared with large
vessels treated with DES [4,5]. It is possible that with further followup, the gap favoring DCB will widen given that the current-generation
DES have a perpetual 2% yearly risk of stent-related adverse events
[21], but longer-term studies are required.

Fig. 1. Outcomes with drug-coated balloons vs. drug-eluting stents in small vessel coronary artery disease. DCB: drug-coated balloon; DES: drug-eluting stent.
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Fig. 2. Pooled analysis of the odds of periprocedural myocardial infarction, major adverse cardiovascular events, all-cause mortality, and myocardial infarction with drug-coated balloons
vs. drug-eluting stents in small vessel coronary artery disease; the summary statistic is the odds ratios and mean differences calculated according to the Mantel-Haenszel method with
random effects, respectively; marker size is proportional to the study weight. DCB: drug-coated balloon; DES: drug-eluting stent.

The use of DCBs in SVD offers many advantages, mainly due to
avoiding permanent prosthesis implantation. Having a smaller proﬁle,
they are more deliverable in smaller vessels compared with DES. They
are more attractive to use in patients at higher bleeding risk, as the recommended duration of dual antiplatelet therapy is only four weeks
[12,22]. Most importantly, DCBs are associated with vascular healing
and positive remodeling, particularly in small coronary lumens
[23,24]. In our analysis, late lumen loss was lower with DCBs compared
with DES at six months, an effect that is expected to be more pronounced with more extended angiographic follow-up.
The use of DCBs in SVD has limitations. DCBs require adequate lesion
preparation, which sometimes can be difﬁcult and carries the risk of
suboptimal results (e.g., persistent residual stenosis and dissections),
necessitating bailout stenting. Iatrogenic dissections have a higher
chance of healing with DCBs [25]. The risk of restenosis is higher type
for C or greater dissections, hence such lesions should be treated with

bailout stenting. In contrast, types A and B dissections can be treated
with a DCB-only strategy. Our study found that the rate of bailout
stenting in more recent studies did not exceed 7%, which appears acceptable. The acceptance of this strategy, especially by less experienced
operators, might be a challenge as the default response to most dissections is stenting. Another limitation of DCBs is that, unlike DES, the class
effect of DCBs cannot be established. The notion that “not all DCBs are
created equal” is crucial in understanding clinical outcomes and choosing the right tool. There is heterogeneity in the excipient, drug mounting technology, and drug transfer rate, leading to mixed clinical trial
results. The lack of a “class effect” was also shown in the SCAAR “Swedish Coronary Angiography and Angioplasty Registry” [26] and emphasized in the European revascularization guidelines [27]. There are
emerging promising data on the use of sirolimus-coated balloons but direct comparison with the currently available paclitaxel-coated balloons
is still required [28].
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Fig. 3. Pooled analysis of the odds of target lesion revascularization and target vessel revascularization and mean difference in late lumen loss with drug-coated balloons vs. drug-eluting
stents in small vessel coronary artery disease; the summary statistic is the odds ratios and mean differences calculated according to the Mantel-Haenszel method and inverse variance
method with random effects, respectively; marker size is proportional to the study weight. DCB: drug-coated balloon; DES: drug-eluting stent.

Fig. 4. Summary of the study results.
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In our analysis, both DES and DCBs were comparable in MACE,
TLR, TVR, and all-cause mortality risk. This equivalency was also
demonstrated in our sensitivity analysis comparing DCBs vs.
second-generation DES. Our ﬁndings, especially with the lower incidence of MI with DCBs, support using DCBs in SVD. Using DCBs fulﬁls
the concept of adequate treatment of atherosclerotic lesions and delivery of anti-restenotic drugs without leaving anything behind.
Larger randomized trials with longer follow-up are needed to
conﬁrm our ﬁndings, and ensure the durability of DCBs in SVD. Our
results are generally similar to the study by Sanchez et al. in the overall outcomes [29]. We did not, however, perform metaregression
given the low number of included studies. Moreover, we performed
a pre-speciﬁed sensitivity analysis that showed equivalency of
DCBs and second-generation DES.
4.1. Limitations
Our study has several limitations. First, there is signiﬁcant heterogeneity, given the differences in the type of DCB and the frequency of adequate lesion preparation. We attempted to overcome this limitation
using random-effect models and by performing further sensitivity analyses. Second, the study was performed using published data not
patient-level data. Third, bleeding outcomes were not consistently reported and could not be analysed. Fourth, our results are reported at a
median follow-up time of 12 months, and more extended follow-up
data are needed. Finally, the number of trials is still limited and a betaerror still possible for many outcomes assessed.
5. Conclusions
PCI of SVD with DCBs is associated with smaller LLL, a lower risk of
MI, and, with the limited data available so far, and similar risk of
MACE, death, TLR, and TVR compared with DES over one year. DCB appears as an attractive alternative to DES in patients with de-novo SVD,
but long-term clinical data are still needed.
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